… In conclusion, antibodies appear to have antiviral effects in the early stages of SARS-CoV-2
infection, and the most symptomatic patients with COVID-19 remain positive for IgG-S and …

… Convalescent plasma is safe, does not improve survival, has … respiratory tract, influence
SARS-CoV-2 antibody development or … of patients already had potent neutralizing SARS-CoV-2 …

… In another analysis of the dynamics of neutralizing antibody titers in eight convalescent
patients with COVID-19, four patients showed decreased neutralizing antibodies approximately 6…

… SARS-CoV-2 VOCs, sera were collected from patients with … In summary, using convalescent
sera from individuals infected … Infection with B.1.1.7, B.1.351 or B.1.617.2 generates a cross-…

… of vaccines against this emerging virus. In this study, we aimed to assess the dynamics and
longevity of the SARS-CoV-2-specific immune responses in COVID-19 patients with a broad …

… to SARS-CoV-2 infection. Here, we collected blood from COVID-19 patients who have
recently become virus-free, and therefore were discharged, and detected SARS-CoV-2-specific …

… Could plasma collected from COVID-19 convalescent patients be efficacious in treating
patients still battling the infection, or as a prophylactic approach to prevent this disease? In this …

… % on days 31–40 post symptom onset to 28% on days 41–53 [12], and decreasing neutralising
antibody levels have also been noted in SARS-CoV-2 infected hospitalised patients [17]. …

… - positive individuals were non-hospitalised patients who had a positive PCR test for
SARS-CoV-2 on nasopharyngeal swab and experienced mild symptoms (Table 1), including coryza…

… Therefore, in the present study, we could not distinguish de novo primed T cells by SARS-CoV-2
infection from pre-existing, cross-reactive ccCoV-specific T cells. However, we could …